Merck Sharp + Dohme Corp.

Merck Canada Inc.

Brandon D Cash

Michael D Altman

Ryan D Otte

Andrew M Haidle

Matthew A Larsen

Jared N Cumming

Jongwon Lim

James Patrick Jewell

Benjamin Wesley Trotter

Min Lu

Tony Siu

Timothy J Henderson

Alan B Northrup

Rui Liang

John Michael Ellis

Matthew Christopher

Wonsuk Chang

Sriram Tyagarajan

Daniel Guay

Michelle R Machacek

Yves Ducharme

Solomon D Kattar

Duane E DeMong

Michael Hale Reutershan

Binyuan Sun

Qinglin Pu

Brandon Mitsuo Taoka

Kaleen Konrad Childers

Christian Beaulieu

Kerrie Spencer

Eric Thomas Romeo

Dilrukshi Vitharana

Matthew L Maddess

Hua Zhou

Peng Zhang

Fang Liu

Christopher J Dinsmore

David James Witter

Phieng Siliphaivanh

Ping Liu

David Joseph Guerin

Lingyun Wu

Joon Jung

Catherine M White

Charles A Lesburg

John W Butcher

Matthew Lloyd Childers

Christian Fischer

Mark E Scott

Jonathan B Grimm

Quang T Truong

Anthony Donofrio

Vouy Linh Truong

Alexey A Rivkin

Hyun Chong Woo

Brendan O'Boyle

Brett A Hopkins

Wenlang Fu

Sean P Ahearn

Sulagna Sanyal

Xin Yan

Meredeth A Mcgowan

Brandon M Taoka

George Madalin Giambasu

James P Jewell

Michele R Machacek

Dilrukshi Witharana

Matthew H Maddess

Brendan O' Boyle

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.

IL4I1 inhibitors and methods of use

Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R, R, R, R, R, R, R, A, X, X, and Xare defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.

Aza-benzothiophene compounds as STING agonists

Compounds of general formula (I), of general formula (II), of general formula (III), of general formula (IV), of general formula (V), of general formula (VI), and their pharmaceutically acceptable salts, wherein all variables are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer. 

Sting agonist compounds

Compounds of general formula (Ia), compounds of general formula (Ia'), compounds of general formula (Ib), compounds of general formula (Ib&#x2032;), compounds of general formula (I), compounds of general formula (I&#x2032;), and their pharmaceutically acceptable salts, wherein R, R, R, R, R, R, R, R, X, X, and Xare defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.

Benzo[b]thiophene compounds as STING agonists

Benzo[b]thiophene compounds as sting agonists

The invention provides certain pyrazine-2-carboxamide compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A, B, and X are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk). 

2-pyrazine carboxamides as spleen tyrosine kinase inhibitors

Provided are triazole derivatives of Formula I which are potent inhibitors of spleen tyrosine kinase and pharmaceutical composition. The triazole derivatives are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

Triazolyl derivatives as Syk inhibitors

The present invention provides novel pyrazole derivatives of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

Pyrazolyl derivatives as Syk inhibitors

The instant invention provides compounds of formula I which are JAK3 inhibitors. Specifically, the compounds of formula I are pyrrolo[2,3-d]pyrimidine derivative compounds. The instant invention also provides methods of treating JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer, by administering the pyrrolo[2,3-d]pyrimidine-derivative compounds of formula I.

Pyrrolopyrimidines as janus kinase inhibitors

Growing community of inventors

Stoughton, MA, United States of America

Brandon D Cash